Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 683

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 683
---

  
    Nir
    Sassi
     
    49
     
    Chief
    Financial Officer
  
    Walt
    A. Linscott, Esq.
     
    65
     
    Chief
    Operating Officer
  
    Roger
    J. Waltzman
     
    58
     
    Chief
    Medical Officer

    Non-Executive
    Directors

    Dr.
    Roger J. Pomerantz
     
    68
     
    Chairman
    of the Board of Directors
  
    Hila
    Karah
     
    56
     
    Director
  
    Anthony
    J. Maddaluna
     
    72
     
    Director
  
    William
    B. Hayes
     
    59
     
    Director
  
    Mark
    J. Gilbert, M.D.
     
    64
     
    Director
  
    Robert
    E. Martell, M.D., Ph.D.
     
    62
     
    Director

Biographical
information with respect to our executive officers and directors is provided below.

Information
about Our Executive Officers

Jeffrey
A. Meckler has served as our Chief Executive Officer since July 2021 and member of our board of directors since inception in
February 2021. Previously, Mr. Meckler served as our sole officer from inception to July 2021, Intec Israel’s Vice Chairman of
the board of directors from April 2017, as Intec Israel’s Chief Executive Officer from July 2017 and as President and Secretary
and director of Intec Parent, Inc. from March 2021 until the Merger. Mr. Meckler has served on numerous public and private corporate
boards and since October 2014 has served as a director of Travere Therapeutics (Nasdaq: TVTX). Mr. Meckler served as Chief Executive
Officer and a director of CoCrystal Pharma, Inc., a pharmaceutical company, from April 2015 to July 2016. He has also served as a director
of QLT, Inc. (Nasdaq: QLTI), a biotechnology company, from June 2012 to November 2016, as well as the Managing Director of The Andra
Group, a life sciences consulting firm since 2009. Mr. Meckler also served as Chief Executive Officer of Trieber Therapeutics from January
201